{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:29:49Z","timestamp":1781069389250,"version":"3.54.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jconrel.2023.08.017","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:53:18Z","timestamp":1692708798000},"page":"717-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research"],"prefix":"10.1016","volume":"361","author":[{"given":"Michael G.","family":"Wientjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie L.S.","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.08.017_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023, CA","volume":"73","author":"Siegel","year":"2023","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/10717544.2019.1704945","article-title":"Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review","volume":"27","author":"Van de Sande","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0015","first-page":"430","article-title":"Peritoneal metastases in pancreatic carcinoma","volume":"40","author":"del Castillo","year":"1993","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0020","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e58","article-title":"Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands","volume":"31","author":"Burg","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650098","article-title":"Peritoneal metastases from colorectal cancer: defining and addressing the challenges","volume":"11","author":"Kranenburg","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0035","first-page":"18","article-title":"Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective","volume":"7","author":"Neuwirth","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00684852","article-title":"Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration","volume":"29","author":"Nagel","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00262740","article-title":"Pharmacokinetics of carboplatin after intraperitoneal administration","volume":"21","author":"Elferink","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0050","first-page":"1712","article-title":"Phase I\/pharmacokinetic study of intraperitoneal cisplatin and etoposide","volume":"47","author":"Zimm","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0055","first-page":"567","article-title":"Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally","volume":"40","author":"Speyer","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0060","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecoloic oncology group study","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0065","first-page":"393","article-title":"Intraperitoneal therapy in the management of ovarian carcinoma","volume":"62","author":"Markman","year":"1989","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0070","first-page":"105","article-title":"Pharmacokinetic principles of locoregional chemotherapy","volume":"17","author":"Kerr","year":"1993","journal-title":"Cancer Surv."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7120567","article-title":"Systematic review of variations in Hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal Cancer","volume":"7","author":"Yurttas","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918777036","article-title":"Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis","volume":"10","author":"Graversen","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0085","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0090","series-title":"Intraperitoneal Cancer Therapy: Principles and Practice","first-page":"389","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC)","author":"Reymond","year":"2015"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0100","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0120","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0125","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2002.20.3.694","article-title":"Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up","volume":"20","author":"Barakat","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0140","series-title":"2016 Society of Gynecologic Oncology Annual Meeting, (2016) Late-breaking Abstract 6","article-title":"A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG\/NRG trial (GOG 252)","author":"Walker","year":"2016"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0145","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0150","author":"NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2023.08.017_bb0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0923-7534(20)31486-1","article-title":"Intraperitoneal treatment and dose-intense therapy in ovarian cancer","volume":"10","author":"Ozols","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0160","doi-asserted-by":"crossref","first-page":"VIII40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2023.08.017_bb0165","first-page":"S64","article-title":"Mapping the location of peritoneal metastases using the peritoneal cancer index and the correlation with overall survival: a retrospective study","volume":"20","author":"Spiliotis","year":"2015","journal-title":"J. BUON"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology","volume":"14","author":"Esquivel","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0175","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","article-title":"The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis","volume":"21","author":"Esquivel","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0190","author":"NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0195","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00685503","article-title":"Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy","volume":"28","author":"Los","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00686048","article-title":"Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment","volume":"25","author":"Los","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1993.1171","article-title":"Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01410140","article-title":"Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate","volume":"118","author":"Markman","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0215","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1245\/s10434-020-08842-7","article-title":"Factors associated with resection and survival after laparoscopic HIPEC for peritoneal gastric cancer metastasis","volume":"27","author":"White","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0220","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0225","series-title":"Advanced Cancer Therapies (ACT) Meeting, San Diego","article-title":"Conversion surgery after intraperitoneal paclitaxel combined with systemic oxaliplatin and oral S-1 (SOX) for patients with peritoneal metastasis from gastric cancer","author":"Yamaguchi","year":"2023"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0230","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1148\/107.3.577","article-title":"A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid","volume":"107","author":"Coates","year":"1973","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0235","first-page":"1663","article-title":"The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma","volume":"32","author":"Feldman","year":"1972","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0240","first-page":"S527","article-title":"Phase I trial of intraperitoneal paclitaxel-loaded TPM for treatment of peritoneal carcinomatosis","volume":"29","author":"Chan","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0245","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0250","series-title":"Personalized Intraperitoneal Drug Dosing Based on Paclitaxel Binding to Proteins in Human Peritoneal Ascites Fluid, Advanced Cancer Therapies (ACT) Meeting, San Diego","author":"Chan","year":"2023"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0255","first-page":"337","article-title":"Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein","volume":"80","author":"Kumar","year":"1993","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0260","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1021\/cr3003533","article-title":"Protein analysis by shotgun\/bottom-up proteomics","volume":"113","author":"Zhang","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0265","author":"Plasma proteome database"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101694","article-title":"Optimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF\/TOF","volume":"9","author":"Luczak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0275","author":"VENNY"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0280","first-page":"363","article-title":"Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel","volume":"9","author":"Chen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s002800050973","article-title":"Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment","volume":"44","author":"Knemeyer","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0290","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/BF01062207","article-title":"Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation","volume":"11","author":"Lima","year":"1983","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0295","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jps.2600730617","article-title":"Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis","volume":"73","author":"Boudinot","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/js950286j","article-title":"Binding of taxol to plastic and glass containers and protein under in vitro conditions","volume":"85","author":"Song","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0305","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0378-4347(94)00456-F","article-title":"Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching","volume":"663","author":"Song","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0310","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0272-6386(12)81084-5","article-title":"Serum albumin concentration-related health care financing administration quality assurance criterion is method-dependent: revision is necessary","volume":"21","author":"Blagg","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0315","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2125.1985.tb05107.x","article-title":"Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health","volume":"20","author":"Blain","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0320","first-page":"143","article-title":"Types of acute phase reactants and their importance in vaccination","volume":"12","author":"Khalil","year":"2020","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0325","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.4155\/bio.11.187","article-title":"Monitoring free drug concentrations: challenges","volume":"3","author":"Musteata","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0330","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","article-title":"Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding","volume":"97","author":"Waters","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0335","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4155\/bio.13.338","article-title":"Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European bioanalysis forum","volume":"6","author":"Buscher","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph14020104","article-title":"The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry","volume":"14","author":"Wang","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0345","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3923\/ijp.2006.293.297","article-title":"The pharmacokinetics of Mitomycin C in the Mitomycin C, Ifosfamide and cisplatin (MIC) regimen","volume":"2","author":"Highley","year":"2006","journal-title":"Int. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0350","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1002\/pmic.201100264","article-title":"Mining the malignant ascites proteome for pancreatic cancer biomarkers","volume":"11","author":"Kosanam","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0360","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00280-015-2737-4","article-title":"A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies","volume":"75","author":"Williamson","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0365","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-019-03767-9","article-title":"A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity","volume":"83","author":"Cristea","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0370","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.chemrev.8b00042","article-title":"Mechanobiology of tumor growth","volume":"118","author":"Chaudhuri","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0375","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2018.00017","article-title":"Feeling stress: the mechanics of cancer progression and aggression","volume":"6","author":"Northcott","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0380","doi-asserted-by":"crossref","first-page":"17693","DOI":"10.1074\/jbc.REV119.007963","article-title":"Control of cellular responses to mechanical cues through YAP\/TAZ regulation","volume":"294","author":"Dasgupta","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0385","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cells7100147","article-title":"Vimentin diversity in health and disease","volume":"7","author":"Danielsson","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0390","first-page":"20180215","article-title":"Tissue mechanics, an important regulator of development and disease","volume":"374","author":"Ayad","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0395","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.devcel.2019.03.026","article-title":"The extracellular matrix modulates the metastatic journey","volume":"49","author":"Kai","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40169-018-0202-9","article-title":"Mechanoregulation and pathology of YAP\/TAZ via hippo and non-hippo mechanisms","volume":"7","author":"Dobrokhotov","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0405","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.3390\/ijms19103028","article-title":"Role of extracellular matrix in development and cancer progression","volume":"19","author":"Walker","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0410","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23190","article-title":"Different TCR-induced T lymphocyte responses are potentiated by stiffness with variable sensitivity","volume":"6","author":"Saitakis","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0415","doi-asserted-by":"crossref","first-page":"19835","DOI":"10.1073\/pnas.1906986116","article-title":"T cell activation and immune synapse organization respond to the microscale mechanics of structured surfaces","volume":"116","author":"Jin","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphy.2019.00045","article-title":"T-cell mechanobiology: force sensation, potentiation, and translation","volume":"7","author":"Harrison","year":"2019","journal-title":"Front. Phys."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0425","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2012.00217","article-title":"Mechanical force in T cell receptor signal initiation","volume":"3","author":"Ma","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0430","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0435","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0440","first-page":"zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times, NAR","volume":"2","author":"Bailly","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0445","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0450","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0455","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0460","first-page":"1193","article-title":"Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer","volume":"4","author":"Tu","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0465","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0470","first-page":"436","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies, Cancer","volume":"3","author":"Emens","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jconrel.2023.08.017_bb0475","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-020-06964-5","article-title":"Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells","volume":"20","author":"Solari","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2023.08.017_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aba6110","article-title":"Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer","volume":"13","author":"Oresta","year":"2021","journal-title":"Sci. Transl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923005151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923005151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:55:59Z","timestamp":1759164959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923005151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":94,"alternative-id":["S0168365923005151"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}